Mark Christiansen is an Endocrinology/Metabolic physician affiliated with Diablo Clinical Research. OpenAlex indexes 72 publications with 4,483 citations (h-index 33); ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2405 Shadelands Dr Ste 300
Walnut Creek, CA 945985906
Telephone
925-939-8585Provider last certified this registry record 23 Jun 2021.
Clinical trials
- User Performance of the TV4 BGMS
Sponsor: Ascensia Diabetes Care
- User Performance of the Thunder Plus BGMS
Sponsor: Ascensia Diabetes Care
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20251 payment
- Medtronic, Inc.Program year20243 payments
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
65.5%l-Thyroxine41.7%Levothyroxine Sodium100%Part D<11 patientsl-Triiodothyronine23.8%Liothyronine Sodium100%Part D<11 patientsMetabolism & gastrointestinal
34.5%Insulin Analog20.2%Novolog100%Part D<11 patientsGLP-1 receptor agonist14.3%Ozempic100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1999–2002 per NIH RePORTER. The latest:
- HEPATIC INSULIN RESISTANCE ASSOCIATED WITH THE USE OF PI
University of California San Francisco
FY2002M01RR000083 - EFFECTS OF ETIOCHOLANEDIONE ON HEPATIC METABOLISM &INSULIN RESISTANC
University of California San Francisco
FY2002M01RR000083 - HEPATIC INSULIN RESISTANCE ASSOCIATED WITH THE USE OF PI
University of California San Francisco
FY2002M01RR000083
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor
Diabetes Technology & Therapeutics
2023 - Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes
Diabetes Technology & Therapeutics
2022 - Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial
Diabetes Technology & Therapeutics
2022
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”